Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 2
2016 3
2017 3
2018 1
2019 4
2020 5
2021 4
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
[Molecular Genetic Testing for Acute Myeloid Leukemia].
Janečková V, Semerád L, Ježíšková I, Dvořáková D, Čulen M, Šustková Z, Mayer J, Ráčil Z. Janečková V, et al. Among authors: semerad l. Klin Onkol. 2016 Winter;29(6):411-418. doi: 10.14735/amko2016411. Klin Onkol. 2016. PMID: 27951719 Review. Czech.
[New Drugs in the Treatment of Acute Myeloid Leukemia in the Elderly].
Šustková Z, Čulen M, Semerád L, Ježíšková I, Dvořáková D, Ráčil Z, Mayer J. Šustková Z, et al. Among authors: semerad l. Klin Onkol. 2017 Summer;30(3):190-196. doi: 10.14735/amko2017190. Klin Onkol. 2017. PMID: 28612615 Review. Czech.
Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
Herudkova Z, Culen M, Folta A, Jeziskova I, Cerna J, Loja T, Tom N, Smejkal J, Semerad L, Dvorakova D, Mayer J, Racil Z. Herudkova Z, et al. Among authors: semerad l. Br J Haematol. 2020 Aug;190(4):562-572. doi: 10.1111/bjh.16341. Epub 2019 Dec 10. Br J Haematol. 2020. PMID: 31822038 Free article.
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience.
Weinbergerová B, Čerňan M, Kabut T, Semerád L, Podstavková N, Szotkowski T, Ježíšková I, Mayer J. Weinbergerová B, et al. Among authors: semerad l. Haematologica. 2023 Oct 1;108(10):2826-2829. doi: 10.3324/haematol.2022.282263. Haematologica. 2023. PMID: 36815379 Free PMC article. No abstract available.
Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, Soverini S, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G. Fontana MC, et al. Among authors: semerad l. Leukemia. 2018 Jul;32(7):1609-1620. doi: 10.1038/s41375-018-0035-y. Epub 2018 Feb 23. Leukemia. 2018. PMID: 29472722 Free PMC article.
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Zackova D, Klamova H, Belohlavkova P, Stejskal L, Necasova T, Semerad L, Weinbergerova B, Srbova D, Voglova J, Cicatkova P, Sustkova Z, Hornak T, Baranova J, Prochazkova J, Mayer J. Zackova D, et al. Among authors: semerad l. Leuk Lymphoma. 2021 Jan;62(1):194-202. doi: 10.1080/10428194.2020.1827242. Epub 2020 Oct 6. Leuk Lymphoma. 2021. PMID: 33021423
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study.
Horňák T, Semerád L, Žáčková D, Weinbergerová B, Šustková Z, Procházková J, Bělohlávková P, Stejskal L, Rohoň P, Faber E, Žák P, Mayer J, Ráčil Z. Horňák T, et al. Among authors: semerad l. Leuk Lymphoma. 2020 Feb;61(2):494-496. doi: 10.1080/10428194.2019.1672054. Epub 2019 Oct 3. Leuk Lymphoma. 2020. PMID: 31580157 No abstract available.
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D. Hornak T, et al. Among authors: semerad l. Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317312
20 results